Less Ads, More Data, More Tools Register for FREE

Pin to quick picksWAND.L Regulatory News (WAND)

  • There is currently no data for WAND

Director/PDMR Shareholding

8 Dec 2016 07:00

RNS Number : 2648R
WANdisco Plc
08 December 2016
 

8 December 2016

 

WANdisco plc

(the 'Company')

 

Director/PDMR Shareholding

 

The Company was notified yesterday that Karl Monaghan, non-executive director, purchased 35,000 ordinary shares of 10 pence each in the Company ("Ordinary Shares") for his SIPP at a price of 140p per share on 5 December 2016 and his wife, Rosena Monaghan purchased 6,551 Ordinary Shares for her SIPP at a price of 145p per share on 6 December. In addition, his son Conor Monaghan acquired 3,091 Ordinary Shares on 5 December 2016 at a price of 145p per share. As a result the combined beneficial holding of Karl Monaghan, his wife and his son in the Company is 44,642 Ordinary Shares representing approximately 0.12% in aggregate of the Company's issued share capital of 37,002,330 ordinary shares.

 

 

1.

Details of the person discharging managerial responsibilities/person closely associated

(a)

Name

Karl Monaghan; Rosena Monaghan (his wife) and Conor Monaghan (his son)

2.

Reason for the notification

(a)

Position/status

non-executive director

(b)

Initial notification/ Amendment

Initial notification

3.

Details of the issuer

(a)

Name

WANdisco plc

(b)

LEI

N/A

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

(a)

Description of the Financial Instrument

Ordinary Shares of 10 pence each

(b)

Identification code of the Financial Instrument

JE00BYPG6G89

(c)

Nature of the transaction

Purchase of shares

 

(d)

Price(s) and volume(s)

Price(s)

Volume(s)

 

 

140 pence

35,000

 

 

145 pence

 9,642

 

 

 

(e)

Aggregated information

- Aggregated volume

- Price

44,642 shares, 141 pence

(f)

Date of the transaction

5 and 6 December 2016

(g)

Place of the transaction

London Stock Exchange

 

 

 

 

For further information, please contact:

 

WANdisco plc

via Vigo Communications

David Richards, CEO and Interim Chairman

 

Vigo Communications

+44 (0)207 830 9700

Jeremy Garcia / Fiona Henson / Antonia Pollock

www.vigocomms.com

Investec (Joint Broker and NOMAD)

+44 (0)207 597 4000

Christopher Baird / Dominic Emery

 

 

 

UBS (Joint Broker)

Rahul Luthra / Sandip Dhillon

+44 (0)207 567 8000

 

 

About WANdisco

WANdisco (LSE: WAND) is the world leader in Active Transactional Data Replication™. Its patented technology provides continuous consistent access to changing data anytime and anywhere with no downtime and no disruption. WANdisco's patented technology serves crucial high availability (HA) requirements, including migration to cloud, Hadoop Big Data and Application Lifecycle Management (ALM), Subversion, Git and Gerrit.

 

WANdisco works directly with Fortune 1000 companies around the world and in all sectors to ensure their data, whether it is on-premise or in the cloud, gives them the real insight they need. WANdisco has an OEM with IBM and is also partnered with Amazon Web Services, Cisco, Google Cloud Platform, Hewlett Packard Enterprise, Microsoft Azure and Oracle to resell its patented technology. WANdisco is committed to the ODPi Interoperable Compliance Program to ensure its products are interoperable across a wider range of commercial Apache™ Hadoop® Platforms.

 

For additional information, please visit www.wandisco.com.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHUGGRWPUPQUWR
Date   Source Headline
4th Oct 20237:00 amRNSWANdisco plc rebrands as Cirata plc
22nd Sep 20236:24 pmRNSHolding(s) in Company
11th Sep 20237:00 amRNSInterim results
7th Sep 20233:30 pmRNSNotice of Results
30th Aug 20236:04 pmRNSResult of Annual General Meeting
18th Aug 20236:05 pmRNSBlock Admission Notification
16th Aug 20238:07 amRNSGM Signs Multi-Project Contract with WANdisco
31st Jul 20237:00 amRNSHolding(s) in Company
28th Jul 20233:25 pmRNSHolding(s) in Company
26th Jul 20237:00 amRNSBoard Changes
25th Jul 20237:30 amRNSRestoration - WANdisco plc
25th Jul 20237:00 amRNSConfirmation of Exchange Rate
24th Jul 202310:45 amRNSResult of GM
17th Jul 20235:00 pmRNSPosting of Annual Report and Accounts
12th Jul 20231:45 pmRNSPublication of Annual Report and Accounts
11th Jul 20237:00 amRNSContract Win
10th Jul 20237:00 amRNSContract Renewal
7th Jul 20237:00 amRNSConfirmation of Fundraise
5th Jul 20236:29 pmRNSPublication of Notice of General Meeting
5th Jul 202311:30 amRNSUpdate to Fundraise Timetable
4th Jul 20237:00 amRNSResult of Fundraising
3rd Jul 202312:00 pmRNSLaunch of Fundraise
29th Jun 20237:00 amRNSPreliminary Unaudited Results FY22
28th Jun 202311:51 amRNSUpdate on Timing of Results and Equity Issue
26th Jun 20233:30 pmRNSTurnaround Plan Momentum
26th Jun 20237:00 amRNSWANdisco Signs New Agreement with Accenture
15th Jun 20239:46 amRNSFCA investigation timeline update
9th Jun 20237:00 amRNSSuccessful Shareholder General Meeting Next Steps
6th Jun 20233:49 pmRNSResult of General Meeting
19th May 20236:22 pmRNSPublication of Circular and Notice of GM
19th May 20236:04 pmRNSBoard Change
15th May 20237:00 amRNSExploring Funding Options
9th May 20235:30 pmRNSWANdisco
9th May 20237:00 amRNSAppointment of Interim Chief Executive
4th May 20237:00 amRNSOrganisation Update
28th Apr 20237:00 amRNSIndependent Investigation Update
20th Apr 20237:00 amRNSFCA Investigation
5th Apr 20237:00 amRNSExecutive Chair Appointment Confirmation
4th Apr 20237:00 amRNSContract Renewals
3rd Apr 20237:00 amRNSBoard Change and Investigation Update
22nd Mar 20237:00 amRNSAppointment of Interim Chair
10th Mar 20239:31 amRNSIndependent Investigation Appointment
9th Mar 20237:30 amRNSSuspension - WANdisco plc
9th Mar 20237:00 amRNSTrading Revision
7th Mar 20237:00 amRNSAppointment of Joint Broker
6th Mar 20237:00 amRNSResponse to press speculation
1st Mar 20238:16 amRNSTotal Voting Rights
1st Feb 20234:05 pmRNSTotal Voting Rights
24th Jan 20237:00 amRNS$9m industrial and consumer goods contract win
11th Jan 20237:00 amRNSFY22 Trading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.